Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 5, 2008, Pages 526.e1-526.e7

  Chu, Micheline C ^a   Cushman, Mary ^b   Solomon, Rachel ^a   Lobo, Rogerio A ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

cardiovascular risk; metabolic syndrome; oral estrogen; postmenopausal; transdermal estrogen

Indexed keywords

ANTITHROMBIN III; BIOLOGICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT RESPONSE;

EID: 54849427908     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.033     Document Type: Article

References (40)

1. Poehlman E.T., Toth M.J., and Gardner A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 123 (1995) 673-675
2. Spencer C.P., Godsland I.F., and Stevenson J.C. Is there a menopausal metabolic syndrome?. Gynecol Endocrinol 11 (1997) 341-355
3. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
4. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
5. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27 (2004) 2444-2449
6. Wilson P.W., Kannel W.B., Silbershatz H., and D'Agostino R.B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159 (1999) 1104-1109
7. Hu P., Greendale G.A., Palla S.L., et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 185 (2006) 347-352
8. Prestwood K.M., Unson C., Kulldorff M., and Cushman M. The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci 59 (2004) 827-832
9. Lindheim S.R., Presser S.C., Ditkoff E.C., et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60 (1993) 664-667
10. Lindheim S.R., Duffy D.M., Kojima T., Vijodm M.A., Stanczyk F.Z., and Lobo R.A. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 62 (1994) 1176-1180
11. Cucinelli F., Paparella P., Soranna L., et al. Differential effect of transdermal estrogen plus progestogen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 140 (1999) 215-223
12. Cagnacci A., Soldani R., Carriero P.L., Paoletti A.M., Fioretti P., and Melis G.B. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74 (1992) 1396-1400
13. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
14. Barrett-Connor E., Slone S., Greendale G., et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas 27 (1997) 261-274
15. Sites C.K., L'Hommedieu G.D., Toth M.J., Brochu M., Cooper B.C., and Fairhurst P.A. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90 (2005) 2701-2707
16. Godsland I.F., Gangar K., Walton C., et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42 (1993) 846-853
17. Spencer C.P., Godsland I.F., Cooper A.J., Ross D., Whitehead M.I., and Stevenson J.C. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 49 (2000) 742-747
18. O'Sullivan A., and Ho K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80 (1995) 1783-1788
19. Manson J.E., Rimm E.B., Colditz G.A., et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 2 (1992) 665-673
20. Margolis K.L., Bonds D.E., Rodabough R.J., et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47 (2004) 1175-1187
21. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., and Salpeter E.E. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8 (2006) 538-554
22. Chu M.C., Cosper P., Nakhuda G.S., and Lobo R.A. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 86 (2006) 1669-1675
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
24. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999) 717-722
25. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
26. Stumvoll M., Mitrakou A., Pimenta W., et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23 (2000) 295-301
27. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
28. Lindheim S.R., Buchanan T.A., Duffy D.M., et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1 (1994) 150-154
29. Chu M.C., Cosper P., Orio F., Carmina E., and Lobo R.A. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol 194 (2006) 100-104
30. Carmina E., and Lobo R.A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82 (2004) 661-665
31. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273 (1995) 199-208
32. Macy E.M., Meilahn E.N., Declerck P.J., and Tracy R.P. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med 117 (1993) 67-70
33. Tracy R.P., and Bovill E. Plasminogen activator inhibitor-1. In: Beutler E., Lichtman M., Coller B., and Kipps T. (Eds). Williams hematology (1995), McGraw-Hill, New York
34. Macy E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43 (1997) 52-58
35. Howard B.V., Hsia J., Ouyang P., et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 110 (2004) 201-206
36. McKenzie J., Jaap A.J., Gallacher S., et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?. Clin Endocrinol (Oxf) 59 (2003) 682-689
37. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol 90 (2002) 7F-10F
38. Vigen C., Hodis H.N., Chandler W.L., Lobo R.A., and Mack W.J. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis. J Thromb Haemost 5 (2007) 1201-1208
39. Mashchak C.A., Lobo R.A., Dozono-Takano R., et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144 (1982) 511-518
40. Lobo R.A., Bush T., Carr B.R., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76 (2001) 13-24